Actors and Network database
The evolving field of gene and cell therapy is supported by a large community of academic, clinical, translational, regulatory and patient organisations. The Actors and Networks database maps these stakeholders in Europe and beyond, their activities, and resources they have produced.
EuroGCT has developed and compiled this database for those interested in identifying the actors involved at each stage of the pathways bringing gene and cell therapies from lab to clinic. Coming from an academic perspective, our focus is to map information that has not been mapped elsewhere. This includes documenting the various types of interconnected regulators, patient groups actively involved along the pathways, and non-profit organisations devoted to therapy development. In its first iteration, this database does not yet include commercial partners and service providers.
Czechia State Institute for Drug Control (SUKL)
Additional information
The Czechia State Institute for Drug Control is a Czech government agency responsible for regulation of the safe production of pharmaceuticals in the country, clinical evaluation of medicines and for monitoring the advertising and marketing of both medicines and medical devices.
Danish Medicines Agency (DKMA)
Additional information
The Danish Medicines Agency authorises and inspects pharmaceutical companies and licenses medicinal products in the Danish market.
Danish Patient Safety Authority (STPS)
Additional information
The Danish Patient Safety Authority is the competent authority for tissues and cells and for blood and blood components in Denmark.
Estonia State Agency of Medicines
Additional information
The Estonia State Agency of Medicines is a governmental body under the Ministry of Social Affairs. Its main responsibility is the protection and promotion of public and animal health, through the supervision of medicines for human and veterinary use.
European Joint Programme on Rare Diseases (EJP RD)
Additional information
Bringing over 130 institutions from 35 countries, EJP RD aims to create an effective, comprehensive, and sustainable rare diseases research ecosystem.
European Medicines Agency (EMA)
Additional information
EMA is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
European Network of Research Ethics Committees (EUREC)
Additional information
EUREC is a network that brings together already existing national Research Ethics Committees (RECs) associations, networks or comparable initiatives on the European level.
European Patients' Forum (EPF)
Additional information
EPF is an independent non-profit, non-governmental umbrella organisation of patient organisations across Europe and across disease-areas
European Society of Gene and Cell Therapy (ESGCT)
Additional information
ESGCT promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
Federal Agency for Medicines
and Health Products (FAMHP)
Additional information
The FAMHP is the Belgian competent authority in charge of ensuring the quality, safety and efficacy of medicines and health products (medical devices and accessories, raw materials, blood and blood components of human origin, human tissue material), for human and veterinary use, in clinical development and on the market.